It would have been bigger if payments were on time:
"The delayed cash receipts were received early in July 2018 and will be recognised in the September quarter."
Still, we did better than most stocks with $25m market cap. How do you think the market will respond?
- Forums
- ASX - By Stock
- VIV
- Ann: Appendix 4C - Quarterly Report
Ann: Appendix 4C - Quarterly Report, page-5
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
Add VIV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online